Novo Nordisk as Logo - Search News

Order byBest matchMost fresh

Novo Nordisk to license obesity drug from Lexicon

Reuters on MSN · 1d

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of its weight-loss treatments.

MarketWatch · 1d

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Business Insider · 1d

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory and sales milestone payments.

3don MSN

Is Novo Nordisk Stock a Buy?

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

1d

Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

4don MSN

Germany’s SAP Overtakes Wegovy Maker Novo Nordisk as Europe’s Most Valuable Company

The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...

5don MSN

Software maker SAP unseats Novo Nordisk as Europe's largest company

German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...

1d

Novo Nordisk price target lowered to DKK 910 from DKK 1,075 at BofA

BofA analyst Sachin Jain lowered the firm’s price target on Novo Nordisk (NVO) to DKK 910 from DKK 1,075 and keeps a Buy rating on the shares.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results